Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.01.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Soraia Pinto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; Instituto de Ciências Bi…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Nanoparticles, Glucagon-Like Peptides, Lactates. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, Academy of Finland.
Abstract (Originalsprache)
Semaglutide is the first oral glucagon-like peptide-1 (GLP-1) analog commercially available for the treatment of type 2 diabetes. In this work, semaglutide was incorporated into poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles (NPs) to improve its delivery across the intestinal barrier. The nanocarriers were surface-decorated with either a peptide or an affibody that target the human neonatal Fc receptor (hFcRn), located on the luminal cell surface of the enterocytes. Both ligands were successfully conjugated with the PLGA-PEG via maleimide-thiol chemistry and thereafter, the functionalized polymers were used to produce semaglutide-loaded NPs. Monodisperse NPs with an average size of 170 nm, neutral surface charge and 3% of semaglutide loading were obtained. Both FcRn-targeted NPs exhibited improved interaction and association with Caco-2 cells (cells that endogenously express the hFcRn), compared to non-targeted NPs. Additionally, the uptake of FcRn-targeted NPs was also observed to occur in human intestinal organoids (HIOs) expressing hFcRn through microinjection into the lumen of HIOs, resulting in potential increase of semaglutide permeability for both ligand-functionalized nanocarriers. Herein, our study demonstrates valuable data and insights that the FcRn-targeted NPs has the capacity to promote intestinal absorption of therapeutic peptides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, Rua Jorge de Vit…
- Department of Biomedical Sciences of Cell and Systems, Section Molecular Cell Biology, University Medical Center Groningen, University of Groningen, 9713, AV, Groningen, the Netherlands.
- Global Research Technologies, Novo Nordisk, Novo Nordisk Park 1, 2760 Måløv, Denmark.
- Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Roslagstullsbacken 21, 114 17 Stockholm, Sweden.
- Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Roslagstullsbacken 21, 114 17 Stockholm, Sweden; Department of Immunology, Genetic…
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, Helsinki FI-00014, Finland; W.J. Kolff Institute for Biomedical Engineering and Ma…
Förderung
- Fundação para a Ciência e a Tecnologia
- Academy of Finland
Zitieren
APA
Pinto, S., Hosseini, M., Buckley, S. T., Yin, W., Garousi, J., Gräslund, T., van Ijzendoorn, S., Santos, H. A., & Sarmento, B. (2024). Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.01.015
Vancouver
Pinto S, Hosseini M, Buckley ST, Yin W, Garousi J, Gräslund T, et al. Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.01.015
BibTeX
@article{Pinto2024,
author = {Pinto, Soraia and Hosseini, Mahya and Buckley, Stephen T and Yin, Wen and Garousi, Javad and Gräslund, Torbjörn and van Ijzendoorn, Sven and Santos, Hélder A and Sarmento, Bruno},
title = {Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.01.015}
}
EUVIMED